{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Ferrochelatase : Questions médicales les plus fréquentes",
"headline": "Ferrochelatase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Ferrochelatase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-05",
"dateModified": "2025-04-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Ferrochelatase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines mitochondriales",
"url": "https://questionsmedicales.fr/mesh/D024101",
"about": {
"@type": "MedicalCondition",
"name": "Protéines mitochondriales",
"code": {
"@type": "MedicalCode",
"code": "D024101",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.575"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Ferrochelatase",
"alternateName": "Ferrochelatase",
"code": {
"@type": "MedicalCode",
"code": "D005294",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Harry A Dailey",
"url": "https://questionsmedicales.fr/author/Harry%20A%20Dailey",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA, USA."
}
},
{
"@type": "Person",
"name": "Amy E Medlock",
"url": "https://questionsmedicales.fr/author/Amy%20E%20Medlock",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA, USA. medlock@uga.edu."
}
},
{
"@type": "Person",
"name": "Stefan Hofbauer",
"url": "https://questionsmedicales.fr/author/Stefan%20Hofbauer",
"affiliation": {
"@type": "Organization",
"name": "BOKU University, Department of Chemistry, Institute of Biochemistry, Muthgasse 18, A-1190 Vienna, Austria. Electronic address: stefan.hofbauer@boku.ac.at."
}
},
{
"@type": "Person",
"name": "Andrea Dali",
"url": "https://questionsmedicales.fr/author/Andrea%20Dali",
"affiliation": {
"@type": "Organization",
"name": "Dipartimento di Chimica \"Ugo Schiff\" (DICUS), Università di Firenze, Via della Lastruccia 3-13, I-50019 Sesto Fiorentino (FI), Italy."
}
},
{
"@type": "Person",
"name": "Thomas Gabler",
"url": "https://questionsmedicales.fr/author/Thomas%20Gabler",
"affiliation": {
"@type": "Organization",
"name": "BOKU University, Department of Chemistry, Institute of Biochemistry, Muthgasse 18, A-1190 Vienna, Austria."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Presence of HPV in prostate tissue from patients submitted to prostate biopsy.",
"datePublished": "2023-01-13",
"url": "https://questionsmedicales.fr/article/36651430",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/acb371205"
}
},
{
"@type": "ScholarlyArticle",
"name": "Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.",
"datePublished": "2022-09-24",
"url": "https://questionsmedicales.fr/article/36253300",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clgc.2022.09.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "The mendelian randomized study revealed the association of prostatitis with prostate cancer risk.",
"datePublished": "2024-10-20",
"url": "https://questionsmedicales.fr/article/39428439",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-76355-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Automatic detection of prostate cancer grades and chronic prostatitis in biparametric MRI.",
"datePublished": "2023-05-26",
"url": "https://questionsmedicales.fr/article/37271051",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cmpb.2023.107624"
}
},
{
"@type": "ScholarlyArticle",
"name": "Is systematic prostate biopsy an overkill in metastatic prostate carcinoma ? A prospective validation.",
"datePublished": "2023-03-14",
"url": "https://questionsmedicales.fr/article/36917412",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11255-023-03531-2"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines mitochondriales",
"item": "https://questionsmedicales.fr/mesh/D024101"
},
{
"@type": "ListItem",
"position": 5,
"name": "Ferrochelatase",
"item": "https://questionsmedicales.fr/mesh/D005294"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Ferrochelatase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Ferrochelatase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Ferrochelatase",
"description": "Comment diagnostiquer une déficience en ferrochelatase ?\nQuels tests sanguins sont utilisés pour évaluer la ferrochelatase ?\nQuels symptômes indiquent un problème de ferrochelatase ?\nLa biopsie est-elle utile pour diagnostiquer des troubles liés à la ferrochelatase ?\nQuels marqueurs biochimiques sont associés à la ferrochelatase ?",
"url": "https://questionsmedicales.fr/mesh/D005294?mesh_terms=Prostatic+Neoplasms&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Ferrochelatase",
"description": "Quels sont les symptômes d'une carence en ferrochelatase ?\nLa douleur abdominale est-elle liée à la ferrochelatase ?\nPeut-on avoir des problèmes neurologiques avec une déficience en ferrochelatase ?\nLes symptômes varient-ils selon l'âge pour les troubles de ferrochelatase ?\nY a-t-il des signes cutanés associés à la déficience en ferrochelatase ?",
"url": "https://questionsmedicales.fr/mesh/D005294?mesh_terms=Prostatic+Neoplasms&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Ferrochelatase",
"description": "Comment prévenir les troubles liés à la ferrochelatase ?\nLes femmes enceintes doivent-elles surveiller leur fer pour la ferrochelatase ?\nY a-t-il des recommandations diététiques spécifiques pour la ferrochelatase ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nLa sensibilisation est-elle importante pour prévenir les troubles de ferrochelatase ?",
"url": "https://questionsmedicales.fr/mesh/D005294?mesh_terms=Prostatic+Neoplasms&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Ferrochelatase",
"description": "Quels traitements sont disponibles pour la déficience en ferrochelatase ?\nLa thérapie génique est-elle une option pour les troubles de ferrochelatase ?\nLes médicaments peuvent-ils aider à traiter les troubles de ferrochelatase ?\nComment la nutrition influence-t-elle la gestion de la déficience en ferrochelatase ?\nLes traitements sont-ils différents pour les enfants et les adultes ?",
"url": "https://questionsmedicales.fr/mesh/D005294?mesh_terms=Prostatic+Neoplasms&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Ferrochelatase",
"description": "Quelles complications peuvent survenir avec une déficience en ferrochelatase ?\nLa déficience en ferrochelatase peut-elle affecter le développement ?\nY a-t-il des risques de complications à long terme ?\nLes complications sont-elles réversibles avec un traitement ?\nComment les complications de ferrochelatase affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D005294?mesh_terms=Prostatic+Neoplasms&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Ferrochelatase",
"description": "Quels sont les facteurs de risque pour les troubles de ferrochelatase ?\nLes personnes âgées sont-elles plus à risque de déficience en ferrochelatase ?\nLes troubles héréditaires augmentent-ils le risque de ferrochelatase ?\nLes habitudes alimentaires influencent-elles le risque de ferrochelatase ?\nLes femmes menstruées sont-elles à risque accru ?",
"url": "https://questionsmedicales.fr/mesh/D005294?mesh_terms=Prostatic+Neoplasms&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en ferrochelatase ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic se fait par des tests génétiques et des dosages enzymatiques."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour évaluer la ferrochelatase ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "On mesure les niveaux de protoporphyrine et d'hémoglobine dans le sang."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème de ferrochelatase ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'anémie, la fatigue et des douleurs abdominales peuvent survenir."
}
},
{
"@type": "Question",
"name": "La biopsie est-elle utile pour diagnostiquer des troubles liés à la ferrochelatase ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une biopsie peut aider à évaluer les niveaux d'hème dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biochimiques sont associés à la ferrochelatase ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de fer sérique et de protoporphyrine sont des marqueurs importants."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une carence en ferrochelatase ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, pâleur, et douleurs abdominales."
}
},
{
"@type": "Question",
"name": "La douleur abdominale est-elle liée à la ferrochelatase ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être un symptôme de troubles liés à la biosynthèse de l'hème."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des problèmes neurologiques avec une déficience en ferrochelatase ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison d'une anémie sévère."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge pour les troubles de ferrochelatase ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent être plus graves chez les enfants que chez les adultes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à la déficience en ferrochelatase ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes cutanés comme des lésions peuvent apparaître en cas de carence sévère."
}
},
{
"@type": "Question",
"name": "Comment prévenir les troubles liés à la ferrochelatase ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et des contrôles réguliers peuvent aider à prévenir."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles surveiller leur fer pour la ferrochelatase ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi du fer est crucial pour prévenir des complications pendant la grossesse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations diététiques spécifiques pour la ferrochelatase ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consommer des aliments riches en fer et en vitamine B12 est recommandé."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils aider à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les personnes à risque."
}
},
{
"@type": "Question",
"name": "La sensibilisation est-elle importante pour prévenir les troubles de ferrochelatase ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la sensibilisation sur les symptômes et les risques est essentielle."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour la déficience en ferrochelatase ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut des transfusions sanguines et des suppléments de fer."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option pour les troubles de ferrochelatase ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est en recherche, mais pas encore une option standard."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils aider à traiter les troubles de ferrochelatase ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les agents chélateurs de fer peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle la gestion de la déficience en ferrochelatase ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en fer peut aider à améliorer les niveaux d'hémoglobine."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils différents pour les enfants et les adultes ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les dosages et les approches peuvent varier selon l'âge du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en ferrochelatase ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme l'anémie sévère et des problèmes neurologiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "La déficience en ferrochelatase peut-elle affecter le développement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des retards de développement chez les enfants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications à long terme ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications chroniques comme des maladies cardiaques peuvent se développer."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles avec un traitement ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles, mais pas toutes."
}
},
{
"@type": "Question",
"name": "Comment les complications de ferrochelatase affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire la qualité de vie en raison de la fatigue et des limitations physiques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles de ferrochelatase ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux et les carences nutritionnelles sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque de déficience en ferrochelatase ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent avoir un risque accru en raison de la malnutrition."
}
},
{
"@type": "Question",
"name": "Les troubles héréditaires augmentent-ils le risque de ferrochelatase ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles héréditaires peuvent prédisposer à des déficiences enzymatiques."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles le risque de ferrochelatase ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation pauvre en fer augmente le risque de déficience."
}
},
{
"@type": "Question",
"name": "Les femmes menstruées sont-elles à risque accru ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes menstruées peuvent être à risque en raison de pertes de fer."
}
}
]
}
]
}
Prostate cancer (PCa) is the second most frequent cancer among men in the Western population. Infections, such as the one caused by the human papillomavirus (HPV), have been shown to promote inflammat...
Prostate tissue fragments were collected by prostate biopsy and subjected to polymerase chain reaction with primers for the HPV L1 gene to identify the presence of the virus....
Among 162 patients, 10 (6.2%) had HPV and in 152 (93.8%) HPV was not identified in prostate biopsies. HPV was detected in 7/95 (7.4%) of patients with PCa, in 2/55 (3.6%) of patients without PCa, and ...
There were no significant levels of HPV L1 protein in prostate tissue. The findings suggest the absence of HPV oncogenic activity in the prostate tissue of patients with PCa....
In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals....
This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ...
It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high...
As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...
In recent observational studies, a potential link between prostatitis and prostate cancer (PCa) has been hinted at, yet the causality remains ambiguous. In our endeavor to scrutinize the conceivable c...
With emerging evidence to improve prostate cancer (PCa) screening, multiparametric magnetic prostate imaging is becoming an essential noninvasive component of the diagnostic routine. Computer-aided di...
We collected 1647 fine-grained biopsy-confirmed findings, including Gleason scores and prostatitis, to form a training dataset. In our experimental framework for lesion detection, all models utilized ...
An optimal model configuration with fine class granularity (prostatitis included) and OHE has scored the lesion-wise partial Free-Response Receiver Operating Characteristic (FROC) area under the curve...
This paper examines several configurations for model training in the biparametric MRI setup and proposes optimal value ranges. It also shows that the fine-grained class configuration, including prosta...
To assess the efficacy of 2-core prostate biopsy in advanced prostate cancer patients. This included a retrospective analysis of 12-core prostate biopsies and a prospective validation that a reduced n...
The first phase analyzed retrospective data from 12-core prostate biopsies between January 2013 and 2018. In the second phase, from January 2018 to January 2022, in a prospective setting, patients wit...
In the retrospective analysis, the number of positive cores in metastatic disease was 12 in 93 (73.8%), 11 in 14 (11.1%), and 10 in 7 (5.6%) patients. Using probability analysis, 94% of patients with ...
A 2-core biopsy is adequate in almost all patients with metastatic prostate cancer with PSA > 75, and this avoids excess complications and morbidity associated with a systematic 12-core prostate biops...
Financial toxicity (FT) is a growing concern among cancer survivors that adversely affects the quality of life and survival. Individuals diagnosed with aggressive cancers are often at a greater risk o...
PCa patients enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP) were recontacted for long-term follow-up. The prevalence of FT in the PCaP cohort was estimated. FT was estimated u...
More than one-third of PCa patients reported experiencing FT. PCa aggressiveness was significantly independently associated with high FT; high aggressive PCa at diagnosis had more than twice the risk ...
Aggressive PCa was associated with high FT. Future studies should collect more information about the characteristics of men with high FT and identify additional risk factors of FT....
Prostate-specific membrane antigen (PSMA) hybrid imaging is a promising new technique gaining importance in the field of prostate cancer (PCa) diagnosis and treatment planning. By combining PSMA radio...
Cribriform (CBFM) pattern on prostate biopsy has been implicated as a predictor for high-risk features, potentially leading to adverse outcomes after definitive treatment. This study aims to investiga...
Patients who underwent multiparametric magnetic resonance imaging (mpMRI), combined 12-core transrectal ultrasound (TRUS) guided systematic (SB) and MRI/US fusion-guided biopsy were retrospectively qu...
Between 2015 and 2022, a total of 131 consecutive patients with CBFM pattern on prostate biopsy and pre-biopsy mpMRI were included. Clinical feature analysis included 1572 systematic biopsy cores (114...
The extent of disease for CBFM-containing tumors is difficult to capture on mpMRI. When comparing MRI lesions of similar dimensions and PIRADS scores, CBFM-containing tumors appear to have larger canc...
Purpose: Determine the time-dependent magnitude of intrafraction prostate displacement and a cutoff for the tracking decision. Methods: Nine patients with localized prostate cancer were treated with u...
Apart from other risk factors, chronic inflammation is also associated with the onset of Prostate Cancer (PCa), wherein pathogen infection and tissue microbiome dysbiosis are known to play a major rol...